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Alport syndrome (AS) is a hereditary glomerulopathy due to
abnormal composition of the glomerular basement
membrane, leading to end-stage renal disease (ESRD).
Studies of animal models of AS have suggested a variety of
potentially effective therapies, but none of these has been
definitely shown to prevent or delay ESRD in human AS.
Studies in Alport mice suggest that angiotensin inhibition
not only has antiproteinuric effects but suppresses cytokine
and collagen production as well as tubulointerstitial
fibrogenesis and inflammation. For these reasons, many
Alport patients are treated empirically with angiotensin
antagonists. Cyclosporine may reduce proteinuria in AS, but
the risk of nephrotoxic side effects complicates long-term
therapy in children. Current data on the role of HMG-CoA
reductase inhibition are sparse, so therapy should be limited
to adults with dyslipoproteinemia. Results of some, but not
all, studies suggest that bone marrow–derived cells may
ameliorate disease in Alport mice. However, until
experimental doubts concerning the superiority of bone-
marrow transplantation over other treatments are resolved
by additional investigation, human research subjects should
not be exposed to cell-based therapies that may carry
substantial risks. In summary, all potential therapies are off-
label use in children. As a consequence, initial therapeutic
trials should focus on the safety and efficiency of medical
treatment, as well as the optimal timing of therapy.
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Alport syndrome (AS) is an inherited basement membrane
disorder characterized by a progressive hereditary nephro-
pathy leading to end-stage renal disease (ESRD) in all affected
males and many affected females, hearing loss in 60–80% and
ocular lesions in 25–40% of affected males. Numerous
mutations in the COL4A5 gene encoding the a5-chain of
type IV collagen have been described in families with
X-linked AS.1 Autosomal recessive AS arises from mutations
in both alleles of COL4A3, which encodes the a3(IV) chain,
or COL4A4, which codes for the a4(IV) chain. Heterozygous
mutations in COL4A3 and COL4A4 cause thin basement
membrane nephropathy.2 Hematuria is the cardinal symp-
tom of thin basement membrane nephropathy and AS.
Almost 1% of the population are heterozygous carriers for
mutations in the autosomal Alport genes and have thin
basement membrane nephropathy, progressing to renal
failure in 5–20%.2
Mutations in COL4A5 that severely alter the a5(IV) chain
(such as large rearrangements, premature stop, or frameshift
mutations) result in an early-onset of ESRD at a mean age of
20 years and increased prevalence of extrarenal symptoms. In
contrast, mutations altering the quaternary structure of type
IV collagen (such as small in-frame mutations or glycine
missense mutations) cause a later onset of ESRD (mean age
about 30 years).2,3
Mutation analysis in patients and families with suspected
AS adds significant information for genetic counseling and
can replace diagnostic renal biopsy in many cases. Further,
molecular genetic diagnosis before the onset of proteinuria
would theoretically allow early effective medical intervention.
Preemptive therapy with the ACE inhibitor ramipril in an
Alport mouse model prolonged lifespan until death from
renal failure by more than 100%.4 These encouraging results
raise the possibility that early therapy before the onset of
proteinuria might also delay renal failure in humans with AS.
As a consequence, mutation analysis of the very large collagen
genes has begun to be offered on a professional basis.5 The
chain of events in AS leading from a defective basement
membrane to progressive renal fibrosis, however, remains
unclear and is a subject of further studies.
Although animal studies have presented us with a variety
of potentially effective therapies for Alport kidney disease,2,6
none of these potential treatments has been formally tested in
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Alport populations, and no pharmacological or biological
agent has been definitely shown to prevent or delay the
development of terminal renal failure in people with AS. The
purpose of this brief review is to assess the opportunities for
clinical trials in AS and the challenges such trials will face.
Alport nephropathy is essentially cured by renal trans-
plantation. The success of renal transplantation in Alport
patients is similar – if not superior – to outcomes in patients
with structural renal disease.3,7 AS does not recur in the
allograft as long as the organ donor does not have the disease.
Antiglomerular basement membrane nephritis in the allo-
graft, though devastating in individual patients, is fortunately
a rare complication of transplantation for AS.3 While
remaining conscious of the morbidities of chronic renal
failure and the limitations on the availability of donor organs,
we should be cognizant of the high success rate of trans-
plantation when we consider the potential risks of interven-
tion for patients and the possible impacts on transplantation.
This review will discuss data generated by studies of
pharmacological and biological interventions in animal and
human AS. As the majority of animal studies involve
transgenic mice, it is important to be aware of the strain
effects on the Alport phenotype in mice.8,9 The discussion of
pharmacological intervention is divided into three categories
– angiotensin antagonism, cyclosporine, and other treatments
– because most of the ‘other’ treatments involve drugs with
which there is relatively little clinical experience, particularly
in children. The discussion of biological interventions will
focus on stem cell therapy.
PHARMACOLOGICAL THERAPY
Angiotensin antagonism
Both angiotensin-converting enzyme inhibition (ACEI) and
angiotensin receptor blockade (ARB) have been shown to
suppress proteinuria, delay loss of renal function, and
prolong survival in Col4a3/ mice with autosomal recessive
AS, raised on a 129 genetic background (Figures 1 and 2).4,10
The most impressive results were observed in mice in which
continuous treatment with ramipril was initiated before
the onset of proteinuria; duration of survival was doubled
in these mice.4 The beneficial effects on urine protein
excretion, renal function, and survival were associated with
reduced glomerular and tubulointerstitial fibrosis. In addi-
tion, therapy resulted in the downregulation of proteins
thought to be key players in human Alport pathogenesis,
such as transforming growth factor-b1, connective tissue
growth factor, matrix metalloproteinases 2 and 9, and type I
collagen.10 Studies of angiotensin antagonism in autosomal
recessive AS mice on the B6 background or in mice with
X-linked AS (XLAS) have not been reported. ACEI therapy
slowed the decline of renal function in canine XLAS.11
To date, only uncontrolled, relatively short-term studies
of the effect of angiotensin antagonism on established
proteinuria have been reported in human AS.12–14 ACEI
appears capable of transiently reducing protein excretion,12
an effect that may be augmented by aldosterone inhibition.15
Although the mechanisms by which angiotensin antagonism
ameliorates Alport kidney disease remain uncertain, evidence
from animal studies suggest that the suppression of cytokine
and collagen production by podocytes and the antifibrotic
and anti-inflammatory effects in the tubulointerstitial
compartment may be more important than the antiprotei-
nuric and antihypertensive effects.
Cyclosporine
Cyclosporine therapy slowed the progression of the glomer-
ular basement membrane changes and the deterioration
of renal function in canine XLAS.16 Although there have been
no randomized controlled trials of cyclosporine therapy
in human AS, uncontrolled studies have shown that
cyclosporine can reduce urine protein levels in Alport
patients.17,18 A study of eight Alport males who received
cyclosporine for 7–10 years suggested slower progression
to ESRD in comparison with related affected males who did
not receive such treatment, without development of histo-
logical evidence of cyclosporine nephrotoxicity after 5 years
of treatment.17 However, another group of investigators
found that cyclosporine therapy in similar doses resulted
in reduced proteinuria and decreased inulin clearances in
children with AS.18 Four of five patients who underwent
renal biopsy after 20–27 months of therapy exhibited
cyclosporine nephrotoxicity.18
The mechanisms by which cyclosporine might have a
beneficial or harmful effect on Alport kidney disease remain
uncertain. Cyclosporine may interfere with alterations in the
podocyte cytoskeleton or type IV collagen turnover.
Other pharmacological therapies
Studies of Col4a3/ mice with autosomal recessive AS,
raised on a 129 genetic background, have shown the
beneficial effects of a variety of pharmacological approaches,
including anti-transforming growth factor-b1 antibody,19
inhibition of matrix metalloproteinases,20 vasopeptidase
inhibition,21 chemokine receptor 1 blockade,22 HMG-CoA
reductase inhibition, 23 and bone morphogenetic protein-7.24
There are no reported studies of these approaches in other
murine or canine models of AS.
BIOLOGICAL INTERVENTION
Gene- and cell-based therapies aim at repairing the under-
lying defect in AS: the defective assembly of a3/4/5(IV)
collagen. Replacement of the defective genes by gene therapy
in models of AS has not been successful thus far. Delivery of
sufficient copies of the normal collagen genes to the
appropriate glomerular location is one of the difficult
challenges that will need to be overcome to make gene
therapy of AS successful.25 Although new gene vectors (and
their efficacy and safety) still have to be established, two
research groups have reported that wild-type bone marrow-
derived cells can ameliorate disease in Alport mice by
differentiation of stem cells into podocytes secreting the
missing collagen a3/4/5(IV) chains 26,27 – basically a curative
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cell-based therapy approach for treating Alport glomerulo-
pathy. These groups postulate that circulating bone marrow-
derived cells are recruited to damaged glomeruli where they
can cross the glomerular basement membrane, become
podocytes, secrete the missing collagen chains, repair the
glomerular basement membrane defects, and slow (if not
reverse) disease. However, although these authors reported
improvements in overall kidney histology compared with
untreated or Col4a3/ bone marrow-treated Alport mice,
the most meaningful end point, i.e. age at end-stage renal
failure, was not tested in either study for reasons not
explained.26,27 Recently, Katayama et al.28 reported that bone
marrow transplantation following lethal irradiation with
either wild-type or Col4a3/ bone marrow prolonged the
lifespan of Alport mice with similar efficiencies. Sublethal
irradiation alone also provided significant benefits. Further, a
previous study of Alport mice that received bone marrow-
derived mesenchymal stem cells also reported improved renal
histology, but there was no delay of death from renal failure.29
Our current knowledge about AS and its possible therapy
by bone marrow transplantation is as yet incomplete. Many
open questions remain that need to be addressed experi-
mentally before clinical bone marrow transplantation studies
should be considered in Alport patients. Owing to the asso-
ciated risks of the bone marrow transplantation procedure, it
is currently being performed only in potentially lethal dis-
eases. Given the perspective of renal transplantation, AS may
not generally qualify for bone marrow transplantation in
terms of improving patient survival. Thus, any experimental
doubts that the effects of bone marrow transplantation are
superior to those of other treatments (such as angiotensin
inhibition) increase the need for more research before expos-
ing research subjects to therapies that may carry greater risks.
SUMMARY OF CURRENT MEDICAL THERAPY
Empiric off-label treatment of Alport patients with overt
proteinuria is widespread in North America and Europe.
Therapy
*ACE inhibition [6, 8–11]
*AT1 antagonist [7]
*Aldosterone antagonist [12]
*HMG-CoenzymeA inhibition [20]
*Cyclosporine [13 –15]
***Vasopeptidase inhibition [18]
***TGFβ-antagonist [16]
***BMP7 [21]
***Gene therapy [22]
***Bone marrow cells [23–25]
***Mesenchymal stem cells [26]
***Endothelin receptor ****
***Chemokine receptor [19]
***Collagen receptor *****
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(++) (D)
(+) (D)
(+) (D)
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(++) (A)
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(++) (A)
ND
ND
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ND
ND
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ND
ND
ND
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(+) (A)
(+) (A)
(+++) (A)
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(+) (A)
(+) (A)
(+) (A)
Hematuria (A)
Hematuria (A)
ND
Nephr. syndrome (A)
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Hematuria (A)
ND
ND
ND
ND
ND
ND
ND
ND
ND** (microalbuminuria?)
ND** (microalbuminuria?)
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Human
Reduction of proteinuria
Animal Human Animal Human Animal
Delay of renal failure Optimal start of therapy
Figure 1 |Current therapeutic approaches in humans and animal models (mice and dogs). In bold: medications used off-label in
children and young adults with AS. A¼placebo-controlled study, B¼ controlled study, D¼ expert view, ND¼ no data, NS¼ not significant.
*Off-label use, **under investigation, ***experimental therapy only, ****Licht C, Gross O, Scheffler M et al. ETB-receptor blockade reduces
tubulointerstitial fibrosis caused by chronic proteinuria in COL4A3 knockout mice (abstract TH-PO471), poster presentation at American
Society of Nephrology Renal Week 2005). *****Gross O, Vogel WF, Weber M et al. Loss of function of the collagen-receptor DDR1 delays
renal fibrosis in the COL4A3 knockout mouse model (abstract TH-PO499, poster presentation at American Society of Nephrology Renal
Week 2005). þ , somewhat effective; þþ , effective; þþþ , very effective.
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2. Cytoskeleton
3. GBM production
4. GBM turnover 4. T-lymphocytes
5. Antifibrotic
6. Anti-inflammatory
7. Antihypertensive
8. Antiproteinuric
1. Act. fibroblasts
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3. EMT
Figure 2 | Synopsis of possible therapeutic targets in AS. Left:
Podocyte damage and alterations of the glomerular basement
membrane: Possible targets include (1) the podocyte itself (bone
marrow-derived cells), (2) the podocyte cytoskeleton
(cyclosporine, ACEI, collagen-receptor blockade), (3) GBM
production (cyclosporine, collagen-receptor blockade), (4) GBM
turnover (MMP antagonists), (5) antifibrotic effects (ACEI, ARBs,
CSE inhibitors, TGFb antagonists, collagen-receptor blockade),
(6) anti-inflammatory effects (ACEI, ARBs, CSE inhibitors, collagen-
receptor blockade), and (7þ 8) antihypertensive/antiproteinuric
effects (ACEI, ARBs, aldosterone and CSE inhibitors, cyclosporine).
Original magnification 10,000. Right: Tubulointerstitial
infiltration and fibrosis: possible targets include (1) activated
fibroblasts (ACEI, ARBs, CSE inhibitors, TGFb antagonists),
(2) macrophages (ACEI, ARBs, CSE inhibitors, collagen-receptor
blockade), (3) epithelial-mesenchymal transition (EMT) (BMP7) and
(4) T lymphocytes (chemokine-receptor blockade, cyclosporine).
Original magnification 400.
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A survey conducted through a pediatric nephrology listserv
found that 97% of 107 respondents used medications to
suppress proteinuria and/or prolong renal survival in
children with AS (unpublished data). Medications used
included ACEI (25%), ARB (10%), ACEI plus ARB (58%),
and cyclosporine (6%). Indications for initiation of treat-
ment included hematuria alone (3%), microalbuminuria
(27%), and overt proteinuria (70%).
These observations have important implications. First,
children with AS and proteinuria are being treated in a way
that prevents an objective assessment of the risks and benefits
of therapy. Second, if treatment of proteinuric Alport
patients with ACEI/ARB represents the standard of practice,
proposals to conduct placebo-controlled trials of such
treatment may be challenged by research subjects protection
programs; if approved, such studies may encounter resistance
to recruitment efforts. On the other hand, observational
studies of markers of disease progression in children who
have not yet developed overt proteinuria, and placebo-
controlled treatment trials in these patients, would not
conflict with the current treatment practices of most
pediatric nephrologists.
At present, no serious side effects of angiotensin
antagonism have been reported to the North American or
European AS registries. However, data showing that angio-
tensin antagonism, alone or in combination with other
agents, alters the natural history of human AS are lacking. All
biological interventions including gene and stem cell therapy
are still in their infancy, but increase the hope for future
therapeutic options. Current data on the role of HMG-
coenzyme A reductase inhibition in human chronic renal
disease are sparse. Therefore, in our opinion, therapy should
be limited to adults with dyslipoproteinemia associated with
to nephrotic syndrome. Data on cyclosporine are inconsistent
as well; therefore, possible harm owing to nephrotoxic side
effects should, at present, hinder any long-term therapeutic
approach in children.
All potential therapies are off-label use in children. Trials
should focus on safety and efficiency of medical treatment
plus optimal start of therapy – microalbuminuria, overt
proteinuria, or even before onset of microalbuminuria.
CHALLENGES OF CLINICAL TRIALS IN AS
Clinical trials in AS face difficult, but not insurmountable,
challenges. First, the disease is not common. Approximately
40–45% of affected individuals are females with XLAS, in
whom the disease course is difficult to predict because of
X-inactivation.30,31 In males with XLAS, rapidity of progres-
sion to ESRD is strongly influenced by COL4A5 genotype.3
Consequently, treatment groups will need to be balanced in
terms of genotype and phenotype. Finally, loss of renal
function in AS occurs over decades; at this time, little is
known about the early markers of disease progression in
human AS.
Overcoming these obstacles will require an international
collaborative effort. Registries have been developed in North
America and Europe to identify Alport families and facilitate
recruitment of affected individuals to natural history studies
of early markers of disease progression and to clinical trials.
Support for these efforts will require a combination of
private, public, and industrial support. Our experience with
Alport families has convinced us that subjects will eagerly
participate in well-designed clinical trials.
DISCLOSURE
CK is Executive Director of the Alport Syndrome Treatments and
Outcomes Registry, USA. OG is principal investigator of the European
Alport Therapy Registry, supported by the Association pour
l‘Information et la Recherche sur les maladies re´nale Ge´ne´tiques
France and the KfH-Foundation Preventive Medicine.
REFERENCES
1. Hudson B, Tryggvason K, Sundaramoorthy M et al. Alport’s Syndrome,
Goodpasture’s Syndrome, and Type IV Collagen. N Engl J Med 2003;
348: 25.
2. Gross O, Weber M. From the molecular genetics of Alport’s syndrome to
principles of organo-protection in chronic renal diseases. Med Klin 2005;
100: 826–831.
3. Jais JP, Knebelmann B, Giatras I et al. X-linked Alport syndrome: natural
history in 195 families and genotype- phenotype correlations in males. J
Am Soc Nephrol 2000; 11: 649–657.
4. Gross O, Beirowski B, Koepke M-L et al. Preemptive ramipril therapy
delays renal failure and reduces renal fibrosis in COL4A3-knockout mice
with Alport syndrome. Kidney Int 2003; 63: 438–446.
5. Nagel Nagel M, Nagorka S, Gross O. Novel COL4A5, COL4A4 and COL4A3
mutations in Alport syndrome. Hum Mutat 2005; 26: 60–65.
6. Cosgrove D, Kalluri R, Miner JH et al. Choosing a mouse model to study
the molecular pathobiology of Alport glomerulonephritis. Kidney Int
2007; 71: 615–618.
7. Kashtan CE, McEnery PT, Tejani A et al. Renal allograft survival according
to primary diagnosis: a report of the North American Pediatric Renal
Transplant Cooperative Study. Pediatr Nephrol 1995; 9: 679–684.
8. Gross O, Borza DB, Anders HJ et al. Stem cell therapy for Alport syndrome:
the hope beyond the hype. Nephrol Dial Transplant 2009; 24: 731–734.
9. Andrews KL, Mudd JL, Li C et al. Quantitative trait loci influence renal
disease progression in a mouse model of Alport syndrome. Am J Pathol
2002; 160: 721–730.
10. Gross O, Schulze-Lohoff E, Koepke M-L et al. Antifibrotic,
nephroprotective potential of ACE-inhibitor vs AT1 antagonist in a
murine model of renal fibrosis. Nephrol Dial Transplant 2004; 19:
1716–1723.
11. Grodecki KM, Gains MJ, Baumal R et al. Treatment of X-linked hereditary
nephritis in Samoyed dogs with angiotensin converting enzyme (ACE)
inhibitor. J Comp Pathol 1997; 117: 209–225.
12. Cohen EP, Lemann Jr J. In hereditary nephritis angiotensin-converting
enzyme inhibition decreases proteinuria and may slow the rate of
progression. Am J Kidney Dis 1996; 27: 199–203.
13. Proesmans W, Knockaert H, Trouet D. Enalapril in paediatric patients with
Alport syndrome: 2 years’ experience. Eur J Pediatr 2000; 159: 430–433.
14. Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome.
Pediatr Nephrol 2004; 19: 271–275.
15. Kaito H, Nozu K, Iijima K et al. The effect of aldosterone blockade in
patients with Alport syndrome. Pediatr Nephrol 2006; 21: 1824–1829.
16. Chen D, Jefferson B, Harvey SJ et al. Cyclosporine a slows the progressive
renal disease of alport syndrome (X-linked hereditary nephritis): results
from a canine model. J Am Soc Nephrol 2003; 14: 690–698.
17. Callis L, Vila A, Carrera M et al. Long-term effects of cyclosporine A in
Alport’s syndrome. Kidney Int 1999; 55: 1051–1056.
18. Charbit M, Gubler MC, Dechaux M et al. Cyclosporin therapy in patients
with Alport syndrome. Pediatr Nephrol 2007; 22: 57–63.
19. Cosgrove D, Rodgers K, Meehan D et al. Integrin alpha1beta1 and
transforming growth factor-beta1 play distinct roles in alport glomerular
pathogenesis and serve as dual targets for metabolic therapy. Am J
Pathol 2000; 157: 1649–1659.
20. Zeisberg M, Khurana M, Rao VH et al. Stage-specific action of matrix
metalloproteinases influences progressive hereditary kidney disease.
PLoS Med 2006; 3: e100.
602 Kidney International (2009) 76, 599–603
min i rev iew O Gross and C Kashtan: Treatment of Alport syndrome
21. Gross O, Koepke ML, Beirowski B et al. Nephroprotection by antifibrotic
and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688.
Kidney Int 2005; 68: 456–463.
22. Ninichuk V, Gross O, Reichel C et al. Delayed chemokine receptor 1
blockade prolongs survival in collagen 4A3-deficient mice with Alport
disease. J Am Soc Nephrol 2005; 16: 977–985.
23. Koepke ML, Weber M, Schulze-Lohoff E et al. Nephroprotective effect of
the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of
progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant
2007; 22: 1062–1069.
24. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-
induced epithelial-to-mesenchymal transition and reverses chronic renal
injury. Nat Med 2003; 9: 964–968.
25. Heikkila¨ P, Tryggvason K, Thorner P. Animal models of Alport syndrome:
advancing the prospects for effective human gene therapy. Exp Nephrol
2000; 8: 1–7.
26. Prodromidi EI, Poulsom R, Jeffery R et al. Bone marrow-derived cells
contribute to podocyte regeneration and amelioration of renal
disease in a mouse model of Alport syndrome. Stem Cells 2006; 24:
2448–2455.
27. Sugimoto H, Mundel TM, Sund M et al. Bone-marrow-derived
stem cells repair basement membrane collagen defects and
reverse genetic kidney disease. Proc Natl Acad Sci USA 2006; 103:
7321–7326.
28. Katayama K, Kawano M, Naito I et al. Irradiation prolongs survival of
Alport mice. J Am Soc Nephrol 2008; 19: 1692–1700.
29. Ninichuk V, Gross O, Segerer S et al. Multipotent mesenchymal stem
cells reduce interstitial fibrosis but do not delay progression of chronic
kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70:
121–129.
30. Bell RJ, Lees GE, Murphy KE. X chromosome inactivation patterns in
normal and X-linked hereditary nephropathy carrier dogs. Cytogenet
Genome Res 2008; 122: 37–40.
31. Kashtan CE: Alport syndrome and the x chromosome: implications of
a diagnosis of Alport syndrome in females. Nephrol Dial Transplant
2007; 22: 1499–1505.
Kidney International (2009) 76, 599–603 603
O Gross and C Kashtan: Treatment of Alport syndrome min i rev iew
